Looming Launches Predicted To Offset Lupin Pressures
Metformin Recalls And Oseltamivir Write-offs Caused Trouble For The Indian Firm
Executive Summary
Lupin delivered a shaky Q3 as profit margins fell following complications with metformin and oseltamivir, but the firm appears confident that several impending high-value launches will set it back on the right track.
You may also be interested in...
Generics Industry Braces For New Wave Of Price Pressure
With pricing pressures already creeping up in recent years, 2022 is set to see the generics industry caught in the middle as prices are further squeezed while costs continue to rise. As major players prepare to announce their first-quarter financial results, In Vivo looks at views from industry leaders on how these pressures are affecting their businesses, and how they can be expected to play out.
Lupin Appoints New Compliance Manager As More Deficiencies Found
Lupin has named a new head of compliance, emphasizing the importance of achieving the highest quality standards just weeks after the FDA notified the firm of observations following an inspection at its Indian facility in Tarapur.
Generics Industry Braces For New Wave Of Price Pressure
With pricing pressures already creeping up in recent years, 2022 is set to see the generics industry caught in the middle as prices are further squeezed while costs continue to rise. As major players prepare to announce their first-quarter financial results, Generics Bulletin looks at views from industry leaders on how these pressures are affecting their businesses, and how they can be expected to play out.